A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) as monotherapy and in combination (combo) with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors (ST)

Disease State: Esophageal squamous cell carcinoma

RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025

RATIONALE-302 (NCT03430843) is a global Phase 3 study of tislelizumab vs investigator-chosen chemotherapy as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025

RATIONALE-306 Trial

RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025

RATIONALE-302 Trial

RATIONALE-302 (NCT03430843) is a global Phase 3 study of tislelizumab vs investigator-chosen chemotherapy as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Reading
8 Aug 2025